[Anesthesiological and postinterventional management in percutaneous hepatic melphalan perfusion (chemosaturation)]
- PMID: 36477906
- PMCID: PMC9892165
- DOI: 10.1007/s00101-022-01235-3
[Anesthesiological and postinterventional management in percutaneous hepatic melphalan perfusion (chemosaturation)]
Abstract
Percutaneous hepatic melphalan perfusion (PHMP) is a last-line treatment of inoperable primary or secondary liver tumors. Selective perfusion and saturation (chemosaturation) of the liver with the chemotherapeutic agent melphalan is performed via catheterization of the hepatic artery without affecting the rest of the body with its cytotoxic properties. Using an extracorporeal circulation and balloon occlusion of the inferior vena cava, the venous hepatic blood is filtered and returned using a bypass procedure. During the procedure, considerable circulatory depression and coagulopathy are frequent. The purpose of this article is to review the anesthesiological and postprocedural management of patients undergoing PHMP with consideration of the pitfalls and special circumstances.
Die perkutane hepatische Perfusion mit dem Chemotherapeutikum Melphalan (PHMP) ist eine Letztlinientherapie bei Patienten mit inoperablen primären oder sekundären Lebertumoren. Dabei wird die Leber transarteriell mit Melphalan perfundiert und aufgesättigt (Chemosaturation), mit dem Ziel, die Lebertumoren selektiv und ohne dessen systemische zytotoxische Eigenschaften zu behandeln. Über einen Extrakorporalkreislauf und eine Ballonokklusion der V. cava inferior wird das venöse hepatische Blut hämofiltriert und venös zurückgeleitet. Verfahrensbedingt kommt es dabei zu einer ausgeprägten Kreislaufdepression und einer Störung der plasmatischen Gerinnung. In diesem Artikel wird das anästhesiologische und postinterventionelle Management bei Patienten mit PHMP beschrieben und auf Fallstricke und Besonderheiten hingewiesen.
Keywords: Angiography; Chemosaturation; Extracorporeal circulation; Liver tumors; Melphalan.
© 2022. The Author(s).
Similar articles
-
Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers.Rofo. 2014 Oct;186(10):937-44. doi: 10.1055/s-0034-1366081. Epub 2014 Apr 11. Rofo. 2014. PMID: 24729409 Clinical Trial.
-
[Thrombotic occlusion of the extracorporeal circulation during hepatic chemosaturation despite targeted anticoagulation : A case report].Anaesthesiologie. 2022 Nov;71(11):852-857. doi: 10.1007/s00101-022-01175-y. Epub 2022 Jul 18. Anaesthesiologie. 2022. PMID: 35925192 Free PMC article. German.
-
Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.Cancer Imaging. 2019 May 30;19(1):31. doi: 10.1186/s40644-019-0218-4. Cancer Imaging. 2019. PMID: 31146793 Free PMC article.
-
Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence.Cancer Treat Rev. 2023 Feb;113:102501. doi: 10.1016/j.ctrv.2022.102501. Epub 2022 Dec 24. Cancer Treat Rev. 2023. PMID: 36587472 Review.
-
Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases.Cancer Control. 2017 Jan;24(1):96-101. doi: 10.1177/107327481702400116. Cancer Control. 2017. PMID: 28178721 Review.
Cited by
-
Peri-Interventional Hemodynamic Management Strategies for Percutaneous Chemosaturation of the Liver in Metastatic Cancer.Cancers (Basel). 2024 Nov 1;16(21):3698. doi: 10.3390/cancers16213698. Cancers (Basel). 2024. PMID: 39518136 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources